



September 19, 2022

To
National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051,
Maharashtra, India

To
BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001,
Maharashtra, India

Dear Sir/Madam,

Subject: **Business updates**

Reference : **Regulation 30 (3) and (4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Scrip Code : **NSE Scrip Code: HCG; BSE Scrip Code: 539787**

This is to inform you that BACC Health Care Private Limited (“**Milann**”), Wholly Owned Subsidiary of the Company, is in discussions with Neonatal Care & Research Institute Private Limited (“**Ovum**”) with respect to a proposal for entering into a business combination arrangement, (“**Potential Transaction**”), whereby the Company, post the completion of the Transaction, may hold a majority of the shareholding in the resultant entity.

The Transaction is subject to the entry into definitive agreements and other conditions, including approvals from Board of Directors/Shareholders, and other approvals as may be considered necessary. The Company shall submit the required information to the stock exchanges, on entering into definitive agreements, in this respect.

Kindly take this on record and acknowledge receipt of this intimation.

For **HealthCare Global Enterprises Limited**

Sunu Manuel
Company Secretary & Compliance Officer

HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.

080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489